Dual use of antifungals in medicine and agriculture: How do we help prevent resistance developing in human pathogens?

Paul E. Verweij; Maiken C. Arendrup; Ana Alastruey-Izquierdo; Jeremy A.W. Gold; Shawn R. Lockhart; Tom Chiller; P. Lewis White

doi:10.1016/j.drup.2022.100885

Dual use of antifungals in medicine and agriculture: How do we help prevent resistance developing in human pathogens?

Paul E. Verweij^*, Maiken C. Arendrup, Ana Alastruey-Izquierdo, Jeremy A.W. Gold, Shawn R. Lockhart, Tom Chiller, P. Lewis White

^*Corresponding author for this work

Research output: Contribution to journal › Journal article › Research › peer-review

48 Citations (Scopus)

24 Downloads (Pure)

Abstract

Azole resistance in Aspergillus fumigatus is a One Health resistance threat, where azole fungicide exposure compromises the efficacy of medical azoles. The use of the recently authorized fungicide ipflufenoquin, which shares its mode-of-action with a new antifungal olorofim, underscores the need for risk assessment for dual use of antifungals.

Original language	English
Article number	100885
Journal	Drug Resistance Updates
Volume	65
ISSN	1368-7646
DOIs	https://doi.org/10.1016/j.drup.2022.100885
Publication status	Published - 2022

Bibliographical note

Publisher Copyright:
© 2022 The Authors

Keywords

Aspergillus fumigatus
DHODH inhibitor
olorofim
One Health
triazole resistance

Access to Document

10.1016/j.drup.2022.100885Licence: CC BY

FulltextFinal published version, 347 KBLicence: CC BY

Library access?

Check availability at the Royal Danish Library

Cite this

@article{52166b21ced44673b5b52c93693b01e8,

title = "Dual use of antifungals in medicine and agriculture: How do we help prevent resistance developing in human pathogens?",

abstract = "Azole resistance in Aspergillus fumigatus is a One Health resistance threat, where azole fungicide exposure compromises the efficacy of medical azoles. The use of the recently authorized fungicide ipflufenoquin, which shares its mode-of-action with a new antifungal olorofim, underscores the need for risk assessment for dual use of antifungals.",

keywords = "Aspergillus fumigatus, DHODH inhibitor, olorofim, One Health, triazole resistance",

author = "Verweij, {Paul E.} and Arendrup, {Maiken C.} and Ana Alastruey-Izquierdo and Gold, {Jeremy A.W.} and Lockhart, {Shawn R.} and Tom Chiller and White, {P. Lewis}",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors",

year = "2022",

doi = "10.1016/j.drup.2022.100885",

language = "English",

volume = "65",

journal = "Drug Resistance Updates",

issn = "1368-7646",

publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Dual use of antifungals in medicine and agriculture

T2 - How do we help prevent resistance developing in human pathogens?

AU - Verweij, Paul E.

AU - Arendrup, Maiken C.

AU - Alastruey-Izquierdo, Ana

AU - Gold, Jeremy A.W.

AU - Lockhart, Shawn R.

AU - Chiller, Tom

AU - White, P. Lewis

PY - 2022

Y1 - 2022

N2 - Azole resistance in Aspergillus fumigatus is a One Health resistance threat, where azole fungicide exposure compromises the efficacy of medical azoles. The use of the recently authorized fungicide ipflufenoquin, which shares its mode-of-action with a new antifungal olorofim, underscores the need for risk assessment for dual use of antifungals.

AB - Azole resistance in Aspergillus fumigatus is a One Health resistance threat, where azole fungicide exposure compromises the efficacy of medical azoles. The use of the recently authorized fungicide ipflufenoquin, which shares its mode-of-action with a new antifungal olorofim, underscores the need for risk assessment for dual use of antifungals.

KW - Aspergillus fumigatus

KW - DHODH inhibitor

KW - olorofim

KW - One Health

KW - triazole resistance

U2 - 10.1016/j.drup.2022.100885

DO - 10.1016/j.drup.2022.100885

M3 - Journal article

C2 - 36283187

AN - SCOPUS:85140326308

SN - 1368-7646

VL - 65

JO - Drug Resistance Updates

JF - Drug Resistance Updates

M1 - 100885

ER -